Answers are grounded in this paper and cite their sources.
The efficacy and safety of nintedanib in patients with IPF were assessed in the two replicate Phase III placebo-controlled INPULSIS trials. In both trials, nintedanib reduced disease progression by reducing decline in forced vital capacity (FVC). The recommended dose of nintedanib was 150 mg twice daily (bid), but dose reductions to 100 mg bid and treatment interruptions were allowed for the management of adverse events. Following a dose reduction, the dose could be re-escalated to 150 mg bid. We assessed whether dose reductions and/or treatment interruptions influenced the effect of nintedanib on reducing FVC decline.
No takes yet. Share an insight, caveat, or question.
Koschel et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: